RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis.

Author: AbbateAntonio, BeutlerAnna, BrucatoAntonio, ChangSteven, CremerPaul, FangFang, GervaisAnais, ImazioMassimo, KleinAllan L, LeWinterMartin, LinDavid, MartiniAlberto, PaoliniJohn F, PerrinRandy

Paper Details 
Original Abstract of the Article :
Recurrent pericarditis (RP) occurs in 15% to 30% of patients following a first episode, despite standard treatment with nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids; many patients become dependent on corticosteroids. Rilonacept (KPL-914), an interleukin-1α and β inhibitor, i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.ahj.2020.07.004

データ提供:米国国立医学図書館(NLM)

Rilonacept: A New Hope for Recurrent Pericarditis

Recurrent pericarditis, an inflammation of the heart sac, is a frustrating condition that can leave patients feeling like a trapped camel in a sandstorm. Current treatments can provide relief, but many patients require long-term medication. This study explores the potential of rilonacept, a new drug targeting inflammation, as a treatment for recurrent pericarditis.

Rilonacept: A Promising New Approach

The researchers designed a large-scale clinical trial (RHAPSODY) to assess the effectiveness and safety of rilonacept in patients with recurrent pericarditis. The trial's primary outcome measure is the time to pericarditis recurrence. Secondary outcomes include symptom severity and overall well-being.

Hope for a Brighter Future

This study offers hope for a better future for patients struggling with recurrent pericarditis. If rilonacept proves to be effective and safe, it could provide a much-needed solution for those seeking long-term relief from this debilitating condition.

Dr.Camel's Conclusion

Recurrent pericarditis can be a real challenge, and this research offers a glimmer of hope for a more effective treatment. Rilonacept, with its targeted approach to inflammation, could be a game-changer for patients seeking lasting relief. As a researcher, I am eager to see the results of this study and the potential impact it could have on improving the lives of those affected by this condition.

Date :
  1. Date Completed 2020-10-08
  2. Date Revised 2020-10-08
Further Info :

Pubmed ID

32866928

DOI: Digital Object Identifier

10.1016/j.ahj.2020.07.004

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.